Jeffrey McGinnis, MD
Adolescent Medicine · Mt Sterling, KYNPI 1497704621
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 248 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 33 manufacturers, the largest accounting for just 16.0% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2022 at $1,057 and has fallen 90.6% since, to $99 in 2025. Among adolescent medicine clinicians in KY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 248 payments — averaging $16.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$658
- Supernus Pharmaceuticals, Inc.$512
- AstraZeneca$405
- Novo Nordisk$301
- Boehringer Ingelheim$233
- Axsome Therapeutics, Inc.$218
- plus $2K from 27 others
What the payments were for
- Food & beverage$4,101100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 55 | $658 |
| Supernus Pharmaceuticals, Inc. | 9 | $512 |
| AstraZeneca | 20 | $405 |
| Novo Nordisk | 18 | $301 |
| Boehringer Ingelheim | 17 | $233 |
| Axsome Therapeutics, Inc. | 11 | $218 |
| Pfizer | 20 | $198 |
| Corium, LLC | 9 | $157 |
| GSK | 8 | $146 |
| Ironshore Pharmaceuticals Inc. | 8 | $145 |
| Novartis | 7 | $132 |
| Merck | 13 | $125 |
| Teva Pharmaceuticals USA, Inc. | 7 | $119 |
| Lilly USA, LLC | 7 | $116 |
| Abbott | 6 | $102 |
| Biohaven Pharmaceutical Holding Company Ltd. | 5 | $84 |
| Xeris Pharmaceuticals, Inc. | 4 | $79 |
| Bayer | 4 | $62 |
| Kowa Pharmaceuticals America, Inc. | 3 | $40 |
| Otsuka America Pharmaceutical, Inc. | 2 | $36 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $29 |
| Sunovion Pharmaceuticals Inc. | 2 | $27 |
| Johnson & Johnson | 1 | $20 |
| Sage Therapeutics, LLC | 1 | $20 |
| Jazz Pharmaceuticals Inc. | 1 | $19 |
| Vanda Pharmaceuticals Inc. | 1 | $18 |
| Almatica Pharma LLC | 1 | $16 |
| Upsher-smith Laboratories LLC | 1 | $16 |
| Genentech USA, Inc. | 1 | $15 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $15 |
| Sanofi-aventis U.S. LLC | 1 | $15 |
| Neurocrine Biosciences, Inc. | 1 | $14 |
| Shire North American Group Inc | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- QELBREE$378
How this compares
$4,101 in reported general payments places this provider in the 95th percentile of 39 adolescent medicine providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 273 | $278,548 |
| MounjaroTirzepatide | 117 | $141,143 |
| EliquisApixaban | 144 | $121,613 |
| JardianceEmpagliflozin | 86 | $118,721 |
| Cosentyx (2 Syringes)Secukinumab | 11 | $83,944 |
| JanuviaSitagliptin Phosphate | 94 | $82,452 |
| TrulicityDulaglutide | 86 | $80,320 |
| XareltoRivaroxaban | 77 | $74,146 |
| XifaxanRifaximin | 22 | $68,240 |
| FarxigaDapagliflozin Propanediol | 66 | $63,636 |
| LinzessLinaclotide | 60 | $50,891 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 58 | $48,989 |
| TradjentaLinagliptin | 47 | $44,599 |
| Tresiba Flextouch U-100Insulin Degludec | 32 | $30,577 |
| UbrelvyUbrogepant | 27 | $29,290 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $301 | $293,652287 claims |
| Lilly USA, LLCMounjaro, Trulicity | $116 | $221,463203 claims |
| Boehringer IngelheimJardiance, Tradjenta, Stiolto Respimat, Jentadueto | $233 | $177,343162 claims |
| MerckJanuvia, Janumet Xr, Janumet, Belsomra | $125 | $141,676168 claims |
| PfizerEliquis, Premarin | $198 | $135,445162 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $405 | $95,790127 claims |
| AbbVieLinzess, Ubrelvy, Savella | $658 | $84,76698 claims |
| NovartisCosentyx (2 Syringes) | $132 | $83,94411 claims |
| Johnson & JohnsonXarelto | $20 | $74,14677 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta | $146 | $61,51587 claims |
| Axsome Therapeutics, Inc.Auvelity | $218 | $12,02311 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Dexilant | $29 | $6,67322 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 39 adolescent medicine providers in Kentucky.
Other adolescent medicine in Mt Sterling
- Stephen BessonCynthiana$12K
- Thomas McCormickLouisville$3K
- Richard HallMount Sterling$2K
- Ashli Collinsla Grange$2K
- James CalderCynthiana$2K
- Brian GillispieLexington$1K
- Katrina HoodLexington$1K
- Gregory TracyLexington$1K
- Debra BaileyPikeville$940
- Charles IsonLexington$858
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.